%0 Journal Article
%T Aspirin: An Overview of Randomized Controlled Trials
%A Singh Asheesh
%A Vinod Sahu
%J International Journal of Research in Pharmacy and Science
%D 2012
%I 
%X Aspirin or Acetylsalicylic acid (ASA) has remained one of the worldĄŻs safest, least expensive and most consumed analgesics. Aspirin, along with its analgesic-antipyretic uses, is now also being considered for prevention of cardiovascular disease, cancer, and treatment of human immuno-deficiency virus infection. Aspirin, one of the first drugs to come into common usage, is still mostly the widely used in the world - approximately 35,000 metric tonnes are produced and consumed annually, enough to make over 100 billion standard aspirin tablets every year. Long-term therapy with aspirin is associated with a significant increase in the incidence of gastrointestinal hemorrhage. Aspirin can reduce thrombin generation with the subsequent attenuation of thrombin-mediated coagulant reactions such as factor XIII activation. Aspirin also acetylates lysine residues in fibrinogen resulting in increased fibrin clot permeability and enhanced clot lysis as well as directly promoting fibrinolysis with high-dose aspirin. Aspirin reduces the odds of serious atherothrombotic vascularents and death in a broad category of high risk patients by about one quarter. Furthermore, there is growing evidence that long-term use of aspirin decreases the risk of colorectal cancer, even at low doses. As aspirin is one of the most prescribed drugs worldwide and its clinical impact is huge, physicians need to consider the benefits and harms for each individual patient in order to maximize the benefits of aspirin. This review demonstrates that there is strong evidence that the use of aspirin reduces the risk of death and recurrent events in patients with various diseases.
%K Aspirin
%K Anti-inflammatory
%K Arthritis
%K Bleeding complication'Cardiovascular prevention
%K GIT Complication
%U http://www.ijrpsonline.com/pdf/216.pdf